Press Releases

ITM and Debiopharm Announce First Patient Imaged in New Study Arm of Phase 1/2 Trial Evaluating ITM-94 as Diagnostic Agent for Clear Cell Renal Cell Carcinoma (ccRCC)

ITM and ILL Extend Collaboration on the Manufacturing and Supply of Medical Lutetium-177 Radioisotope

ITM to Provide COMPETE Trial Insights at SNMMI 2025 Annual Meeting in Oral Presentation and Satellite Symposium

ITM Secures Up to $262.5m in Non-dilutive Debt Financing with Blue Owl Managed Funds

ITM and Radiopharm Sign Supply Agreement for n.c.a. Lutetium-177

ITM and Alpha-9 Oncology Enter Into Supply Agreement for Therapeutic Medical Radioisotope Actinium-225

Barbara Weber, M.D., Elected to ITM Supervisory Board

ITM Appoints Dr. Celine Wilke as Chief Medical Officer

ITM Announces Updates to Commercial Leadership

ITM Presents Positive Topline Phase 3 COMPETE Trial Data with n.c.a. 177Lu-edotreotide (ITM-11), a Targeted Radiopharmaceutical Therapy, in Patients with Grade 1 or 2 Gastroenteropancreatic Neuroendocrine Tumors at the ENETS 2025 Conference

ITM to Present Top Line Results from Phase 3 COMPETE Trial with [177Lu]Lu-edotreotide for the Treatment of Grade 1 & Grade 2 Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) at European Neuroendocrine Tumor Society (ENETS) Conference

ITM to Present at Raymond James Private Biotech Symposium

ITM to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference

ITM Announces Positive Topline Results of Phase 3 COMPETE Trial with ITM-11, a Targeted Radiopharmaceutical Therapy, in Patients with Grade 1 or Grade 2 Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Actineer Appoints Radiopharmaceutical Executive Joseph Oliverio as President and CEO

ITM and Ariceum Therapeutics Enter Into Supply Agreement for Therapeutic Medical Radioisotope Actinium-225

ITM to Present at the 43rd Annual J.P. Morgan Healthcare Conference

ITM to Participate in Upcoming Investor Conferences

ITM, TUM, and TUM University Hospital Sign New Framework Agreement to Advance Innovative Radiopharmaceutical Cancer Treatments

Bruce Power and partners celebrate two years of commercial production of cancer-fighting isotopes

Actineer, a Joint Venture of ITM and CNL, Begins Actinium-225 Production

ITM and NTP Strengthen Global Radioisotope Production Capacities by Renewing their Technology License Agreement and Signing a Manufacturing and Supply Agreement for n.c.a. Lutetium-177

Saugeen Ojibway Nation, Bruce Power, Isogen and ITM double down on production of cancer-fighting medical isotopes

ITM to Present at Upcoming Radiopharmaceutical Investor Conferences in New York City

ITM Obtains Exclusive Worldwide License from Debiopharm for CA IX-Targeted Peptide-based Radiopharmaceutical Programs Targeting Solid Tumors